

Obstetric and Infant Outcomes Following Maternal Third Trimester Exposure to Tenofovir 1% Vaginal Gel

Lisa M. Noguchi, Joseph Biggio, Katherine Bunge, James Dai, Karen Isaacs, Kristine Torjesen, Samuel Kabwigu, Jill Schwartz, Juan Vargas, Cindy Jacobson, D. Heather Watts, Jeanna M. Piper, & Richard H. Beigi, for the MTN-002, MTN-008 & MTN-016 (EMBRACE) Study Teams

MTN-016 Protocol Team Meeting, 2014 MTN Regional Meeting

Cape Town, South Africa

October 26, 2014

Introduction

- Drug safety evaluation in pregnancy:
assess potential impact of drug exposure
 - Obstetric (OB) outcomes
 - Infant outcomes
- Evaluated OB and infant outcomes,
including infant malformations
 - Registrants enrolled in planned 3rd trimester
TFV gel studies

Design

Planned third trimester exposures

- MTN-002
- MTN-008

Unplanned first trimester exposures

- Phase 2B & 3 trials

MTN-016
Pregnancy
Registry

Methods

- Restricted to planned 3rd trimester exposure, comparisons using Fisher's exact test
 - MTN-002: open label, single dose, 1% TFV gel prior to cesarean
 - MTN-008: 2:1 placebo-controlled, 7 daily doses, 1% TFV gel
- Outcomes
 - OB: preterm birth, postpartum hemorrhage, non-reassuring fetal status, chorioamnionitis, gestational diabetes (MTN-008)
 - Infant : any visit with variation from normal physical exam (PE) (MTN-008)

Malformation outcomes

- Two consultant geneticists determined endpoints via independent review of PE data, pregnancy and medication history, genetic screening data, and photo data (MTN-002 & MTN-008)


The screenshot displays the ATLAS (AIDS Treatment and Learning Study) and SCHARP (Statistical Center for HIV/AIDS Research & Prevention) Atlas web interface. The page is titled "Results" and shows "Photographic Documentation Results" for a specific participant. The participant ID is redacted. The results are for "Visit 1, Exam Date: 23-Apr-12". The "Infant Malformation Assessment Form" is identified as "MTN-016 Mjor Malformation Assessment Worksheet3.doc". The "Site Comments" section notes "Umbilical hernia". The "Site Images" section is redacted. The "CRF Images" section lists two forms: "Infant: contains the following CRF (if present)... -Infant Physical Exam" and "Mother: contains the following CRFs (if present)... -Woman Concomitant Medications Log -Genetic Screening History -Pregnancy Report and History". At the bottom, the "Consultant 1 Status" and "Consultant 2 Status" are both "Completed (on null)". The "Overall Assessment" is "AGREE".

Consultant 1 Status:	Completed (on null)	Overall Assessment:	AGREE
Consultant 2 Status:	Completed (on null)		

Results

- Enrollment into registry
 - 100% (16/16) of MTN-002 mothers, 25% (n=4) of whom enrolled prior to pregnancy outcome
 - 90% (88/98) of MTN-008 mothers, 97% (n=86) of whom enrolled prior to pregnancy outcome
- Infant retention at 12 months
 - 88% (MTN-002) and 80% (MTN-008)
- Infant malformations
 - One defect (ear canal) in MTN-002: prevalence (6%) comparable to US background prevalence (3%) for malformations ($p=0.51$)
 - No defects noted among infants from MTN-008

Obstetric and newborn outcomes following 7-day third trimester exposure to TFV gel



Conclusions

- First report from a novel pregnancy registry
 - Suggests single-dose and 7-day repeat dose TFV 1% gel exposure in 3rd trimester do not impact several important OB/infant outcomes
- Pregnancy registries can provide valuable data for evaluating maternal and infant safety associated with third trimester microbicide use

Acknowledgements

- MTN is funded by NIAID (5U01AI068633), NICHD and NIMH, all of the U.S. National Institutes of Health
- MTN-002 and MTN-008 study site teams and participants
- Jennifer Balkus, PhD, MPH
- Jason Pan, MS